February 2026 marked record venture funding levels worldwide, with capital flowing primarily into healthcare and technology sectors across North America, Europe, and Asia-Pacific markets. The acceleration reverses a two-year downturn that constrained global venture activity through 2023 and 2024.
Healthcare deals dominate cross-border investment activity. US-based investors F-Prime, Curie.Bio, and DaVita Venture Group co-led a $77.5 million Series A round for R1 Therapeutics, reflecting institutional appetite for novel therapeutic platforms. Similar patterns emerge in European and Asian biotech funding.
Multi-sector firms including Felicis Ventures and Amplify Partners have recorded portfolio exits, validating diversified strategies across global markets. These exits provide liquidity for limited partners from pension funds to sovereign wealth vehicles seeking venture exposure.
The current trajectory suggests 2026 could produce over 270 unicorns globally—a 45% increase over 2025. This pace reflects improved market conditions and rising valuations in growth-stage rounds across major financial centers from San Francisco to London to Singapore.
Healthcare's defensive characteristics during economic volatility make the sector particularly attractive to international institutional capital. Specialized venture firms leverage domain expertise to identify therapeutic opportunities, with corporate venture arms like DaVita Venture Group combining funding with market access partnerships.
For global investors, the unicorn creation rate signals expanded exit opportunities. The current cohort will likely produce IPO candidates within 18-36 months across NYSE, NASDAQ, LSE, and other exchanges, opening public market access to retail investors worldwide.
The Q1 2026 surge positions venture capital as a primary driver of late-stage company formation globally, with implications for institutional allocators and companies evaluating funding strategies in competitive international markets.
